Rosuvastatin pretreatment in patients undergoing elective PCI to reduce the incidence of myocardial periprocedural necrosis: The ROMA trial

Catheterization and Cardiovascular Interventions

Volumn 81, Issue 1, 2013, Pages

  Sardella, Gennaro ^a   Conti, Giulia ^a   Donahue, Michael ^a   Mancone, Massimo ^a   Canali, Emanuele ^a   De Carlo, Carlotta ^a   Di Roma, Angelo ^a   Calcagno, Simone ^a   Lucisano, Luigi ^a   Fedele, Francesco ^a  

^a POLICLINICO UMBERTO I   (Italy)

Author keywords

elective coronary angioplasty; myocardial necrosis; rosuvastatin

Indexed keywords

CREATINE KINASE MB; ROSUVASTATIN; TROPONIN T;

AGED; ARTICLE; CEREBROVASCULAR ACCIDENT; CONTROLLED STUDY; DOSE RESPONSE; DRUG EFFICACY; DRUG MEGADOSE; FEMALE; FOLLOW UP; HEART DEATH; HEART INFARCTION; HEART MUSCLE NECROSIS; HEART PROTECTION; HUMAN; LOADING DRUG DOSE; MAJOR CLINICAL STUDY; MALE; PROTEIN BLOOD LEVEL; RANDOMIZED CONTROLLED TRIAL; STABLE ANGINA PECTORIS; TRANSLUMINAL CORONARY ANGIOPLASTY; TREATMENT OUTCOME;

AGED; ANGIOPLASTY, BALLOON, CORONARY; CARDIAC CATHETERIZATION; CARDIOTONIC AGENTS; CORONARY ANGIOGRAPHY; CORONARY STENOSIS; DRUG ADMINISTRATION SCHEDULE; FEMALE; FLUOROBENZENES; FOLLOW-UP STUDIES; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; ITALY; KAPLAN-MEIER ESTIMATE; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; MYOCARDIAL INFARCTION; NECROSIS; PERCUTANEOUS CORONARY INTERVENTION; PREMEDICATION; PROSPECTIVE STUDIES; PULSE THERAPY, DRUG; PYRIMIDINES; RISK ASSESSMENT; SULFONAMIDES; SURVIVAL RATE; TREATMENT OUTCOME;

EID: 84871720018     PISSN: 15221946     EISSN: 1522726X     Source Type: Journal    
DOI: 10.1002/ccd.24403     Document Type: Article

References (22)

1. Califf RM, Abdelmeguid AE, Kunitz RE, Popma JJ, Davidson CJ, Cohen EA, Kleiman NS, Mahaffey KW, Topol EJ, Pepine CJ, Lipicky RJ, Granger CB, Harrington RA, Tardiff BE, Crenshaw BS, Bauman RP, Zuckerman BD, Chaitman BR, Bittl JA, Ohman EM,. Myonecrosis after revascularization procedures. J Am Coll Cardiol 1998; 31: 241-251.
2. Klein RW, Kramer BL, Howard E, Lesch M,. Incidence and clinical significance of transient creatine kinase elevations and the diagnosis of non-Q QQ wave myocardial infarction associated with coronary angioplasty. J Am Coll Cardiol 1991; 17: 321-326.
3. Prasad A, Herrmann J,. Myocardial Infarction due to percutaneous coronary intervention. N Eng J Med 2011; 364: 453-464.
4. Saucedo JF, Mehran R, Dangas G, Hong MK, Lansky A, Kent KM, Satler LF, Pichard AD, Stone GW, Leon MB,. Long term clinical events following creatin kinase-myocardial band isoenzyme elevation after successful coronary stenting. J Am Coll Cardiol 2000; 35: 1134-1141.
5. Ellis SG, Chew D, Chan A, Whitlow PL, Schneider JP, Topol EJ,. Death following creatine kinase-MB elevation after coronary intervention. Identification of an early risk period: Importance of creatine kinase-MB level, completeness of revascularization, ventricular function and probable benefit of statin therapy. Circulation 2002; 106: 1205-1211.
6. Kong TQ, Davidson CJ, Meyers SN, Tauke JT, Parker MA, Bonow RO,. Prognostic implication of creatine kinase elevation following elective coronary artery intervention. JAMA 1997; 277: 461-466.
7. Merla R, Reddy NK, Wang FW, Uretsky BF, Barbagelata A, Birnbaum Y,. Meta-analysis of published reports on the effect of statin treatment before percutaneous coronary intervention on peri-procedural myonecrosis. Am J Cardiol 2007; 100: 770-776.
8. Veselka J, prochazkova S, Duchnova R, Homolova I, Tesar D, Bybee KA,. Pre-procedural statin therapy reduces the risk and extent of cardiac biomarkers release following percutaneous coronary intervention. Heart Vessels 2006; 21: 146-151.
9. Pasceri V, Patti G, Nusca A, Pristipino C, Richichi G, Di Sciascio G,. Randomized trial of atorvastatin for reduction of myocardial damage during coronary intervention: Results from the ARMYDA (Atorvastatin for Reduction of MYocardial Damage during Angioplasty) study. Circulation 2004, 110: 674-678.
10. Briguori C, Colombo A, Airoldi F, Violante A, Focaccio A, Balestrieri P, Paolo Elia P, Golia B, Lepore S, Riviezzo G, Scarpato P, Librera M, Bonizzoni E, Ricciardelli B,. Statin administration before percutaneous coronary intervention: Impact on periprocedural myocardial infarction. Eur Heart J 2004; 25: 1822-1828.
11. Thygesen K, Alpert JS,;, White HD,; on behalf of the Joint ESC/ACCF/AHA/WHF Task Force for the Redefinition of Myocardial InfarctionUniversal definition of MI. Universal definition of Myocardial Infarction. Circulation 2007; 116: 2634-2653.
12. Ricciardi MJ, Wu E, Davidson CJ, Choi KM, Klocke FJ, Bonow RO, Judd RM, Kim RJ,. Visualization of discrete microinfarction after percutaneous coronary intervention associated with mild creatine kinase-MB elevation. Circulation 2001; 103: 2780-2783.
13. Ioannidis JPA, Karvouni E, Katritis DG,. Mortality risk conferred by small elevations of creatine kinase-MB isoenzyme after percutaneous intervention. J Am Coll Cardiol 2003; 42: 1406-1411.
14. Lim C, van Gaal WJ, Testa L, Cuculi F, Arnold JR, Karamitsos T, Francis JM, Petersen SE, Digby JE, Westaby S, Antoniades C, Kharbanda RK, Burrell LM, Neubauer S, Banning AP,. With the "Universal Definition," Measurement of creatine kinase-myocardial band rather than troponin allows more accurate diagnosis of periprocedural necrosis and infarction after coronary intervention. J Am Coll Cardiol 2011; 57; 653-661.
15. Rosenson RS, Tangney CC,. Antiatherothrombotic properties of statins: Implication for cardiovascular event reduction. JAMA 1998; 279: 1643-1650.
16. Davignon J,. Beneficial cardiovascular pleiotropic effects of statins. Circulation 2004; 109: 23 Suppl 1 (): III39-III43.
17. Bourcier T, Libby P,. HMG CoA reductase inhibitors reduce plasminogen activator inhibitor-1 expression by human vascular smooth muscle and endothelial cells. Arterioscler Vasc Biol 2000; 20: 556-562.
18. Patti G, Pasceri V, Colonna G, Miglionico M, Fischetti D, Sardella G, Montinaro A, Di Sciascio G,. Atorvastatin pre-treatment improves outcomes in patients with acute coronary syndromes undergoing early percutaneous coronary intervention: Results of the ARMYDA-ACS randomized trial. J Am Coll Cardiol 2007; 49: 1272-1278.
19. Lev EI, Kornowski R, Vaknin-Assa H, Ben-Dor I, Brosh D, Teplitsky I, Fuchs S, Battler A, Assali A,. Effects of previous treatment with statins on outcome of patients with primary percutaneous coronary intervention. Am J Cardiol 2009; 103: 165-169.
20. Kim JS, Kim J, Choi D, Lee CJ, Lee SH, Ko YG, Hong MK, Kim BK, Oh SJ, Jeon DW, Yang JY, Cho JR, Lee NH, Cho YH, Cho DK, Jang Y,. Efficacy of High-dose atorvastain loading before primary percutaneous coronary intervention in ST-segment elevation myocardial infarction. The STATIN STEMI Trial. J Am Coll Cardiol Interv 2010; 3: 332-339.
21. Briguori C, Visconti G, Focaccio A, Golia B, Chieffo A, Castelli A, Mussardo M, Montorfano M, Ricciardelli B, Colombo A,. Novel Approches for Preventing or Limiting Events (NAPLES II) Trial. J Am Coll Cardiol 2009; 54: 2157-2163.
22. Patti G, Cannon CP, Murphy SA, Mega S, Pasceri V, Briguori C, Colombo A, Yun KH, Jeong MH, Kim JS, Choi D, Bozbas H, Kinoshita M, Fukuda K, Jia XW, Hara H, Cay S, Di Sciascio G,. Clinical benefit of statin pretreatment in patients undergoing percutaneous coronary intervention. A collaborative patient-level meta-analysis of 13 randomized study. Circulation 2011; 123: 1622-1632.